For instance, SURPASS-1 demonstrated the effectiveness of its standalone therapy, with significant reductions in HbA1c levels and notable weight loss [43]
But heres the toxicology blind spot: oral small-molecule GLP-1 drugs create a very different safety landscape than injectable peptides
ARD-101 is an oral medication that targets bitter taste receptors to suppress appetite, making it a unique addition to the list of weight loss drugs
Retatrutide is an investigational compound from Lilly
When activated, glucagon receptors increase energy expenditure through thermogenesis, promote lipolysis, which is the breakdown of stored fat, and enhance fatty acid oxidation in the liver
The GLP-1 receptor exists primarily in the pancreas, stomach, and intestinesnot in the liver enzymes that metabolize most anticoagulants